CN115737727B - 一种治疗阿司匹林诱导胃黏膜损伤的药物组合 - Google Patents
一种治疗阿司匹林诱导胃黏膜损伤的药物组合 Download PDFInfo
- Publication number
- CN115737727B CN115737727B CN202211476101.7A CN202211476101A CN115737727B CN 115737727 B CN115737727 B CN 115737727B CN 202211476101 A CN202211476101 A CN 202211476101A CN 115737727 B CN115737727 B CN 115737727B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- group
- gastric mucosal
- mice
- polyphenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002496 gastric effect Effects 0.000 title claims abstract description 40
- 230000006378 damage Effects 0.000 title claims abstract description 31
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 26
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 26
- 208000014674 injury Diseases 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 31
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 31
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 28
- 239000005017 polysaccharide Substances 0.000 claims abstract description 28
- 150000004676 glycans Chemical class 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 15
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 7
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 244000269722 Thea sinensis Species 0.000 claims abstract 7
- 239000002504 physiological saline solution Substances 0.000 claims description 7
- 206010061164 Gastric mucosal lesion Diseases 0.000 claims description 5
- 239000005426 pharmaceutical component Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 244000241838 Lycium barbarum Species 0.000 abstract description 11
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 11
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 9
- 230000003993 interaction Effects 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 239000001301 oxygen Substances 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 239000008518 lycium barbarum polysaccharide Substances 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000002441 reversible effect Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000007760 free radical scavenging Effects 0.000 abstract description 2
- 230000002427 irreversible effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 55
- 210000001156 gastric mucosa Anatomy 0.000 description 24
- 241001122767 Theaceae Species 0.000 description 17
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical group O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 15
- 208000025865 Ulcer Diseases 0.000 description 15
- 229940118019 malondialdehyde Drugs 0.000 description 15
- 210000004400 mucous membrane Anatomy 0.000 description 15
- 231100000397 ulcer Toxicity 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 7
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101150116862 KEAP1 gene Proteins 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 2
- -1 Oxygen Free Radical Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 101100203566 Caenorhabditis elegans sod-3 gene Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100533820 Rattus norvegicus Sod3 gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 101150005399 sod2 gene Proteins 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗阿司匹林诱导胃黏膜损伤的药物组合,涉及药物技术领域。本发明包括以下药物成分:茶多酚、枸杞多糖和生理盐水,其中重量配比如下:茶多酚0.56~0.7份,枸杞多糖2.1~2.625份,生理盐水100份,该药物组合制作过程中在常温下遮光处理。本发明中当多酚和多糖进行物理混合时,体系主要以氢键、疏水相互作用、离子作用等非共价相互作用为驱动力,诱导两者形成可逆或不可逆多酚‑多糖复合物,茶多酚和枸杞多糖均具有较强的活性氧自由基清除作用,并且茶多酚还具有抗炎作用,在胃黏膜损伤修复方面发挥重要作用,通过茶多酚联合枸杞多糖在提高茶多酚生物活性的基础上,同时发挥二者对胃黏膜损伤的协同保护作用。
Description
技术领域
本发明涉及药物技术领域,具体是指一种治疗阿司匹林诱导胃黏膜损伤的药物组合。
背景技术
胃黏膜损伤是导致胃溃疡及急慢性胃炎的主要病理生理学环节,其损伤的产生是由于胃黏膜攻击性因素及保护/防御性因素失去平衡所造成的,胃黏膜防御因子包括黏液-碳酸氢盐屏障、胃黏膜上皮细胞屏障、胃黏膜血流量等;引起胃黏膜损伤的攻击因子包括吸烟、胃酸、胃蛋白酶、幽门螺旋杆菌、非甾体抗炎药、应激反应和心理因素等。
阿司匹林(Aspirin)是非甾体抗炎药(NSAIDs)的代表药物,是临床上常见的解热镇痛消炎药,大多数NSAIDs为脂溶性的弱有机酸,pH在4.5~5.5左右,在胃液内多呈非离子状态,由于胃黏膜表面呈亲脂性,故NSAIDs很容易通过细胞膜进入细胞内,胞内较高的pH环境增加了药物解离度,使NSAIDs转化为水溶性离子状态,细胞内包含有与细胞外呈动态平衡的非离子型以及离子型的NSAIDs,药物浓度远远高于细胞外的浓度,可以导致细胞毒效应,使细胞膜的通透性发生改变,细胞内K+进入胃液,而H+逆向扩散进入粘膜细胞内使胃黏膜上皮细胞水肿、变性、坏死、脱落造成粘膜细胞损伤,破坏粘膜屏障,而细胞内高浓度的NSAIDs还可抑制线粒体氧化磷酸化,使ATP产生减少,伴随能量生成障碍的发生,破坏了胃黏膜上皮细胞间紧密连接的完整性,使黏膜细胞间通透性增大。同时,线粒体受损启动了一系列氧自由基(OFR)反应,使氧自由基生成-清除平衡被打破,进一步加重了黏膜屏障的损伤;氧自由基作用于脂质发生过氧化反应,其终产物为丙二醛(MDA),会引起蛋白质、核酸等生命大分子的交联聚合,且具有细胞毒性,因此MDA常作为评估活性氧(ROS)程度的指标,此外,胃黏膜损伤可以激活NF-κB信号转导通路,进而通过经典途径调控IL-1β、TNF-α、IL-6和IL-8等炎症因子的表达,当大量促炎因子产生时,细胞内信号级联反应增强从而使炎症加剧,引起组织损伤。因此亟需一种治疗阿司匹林诱导胃黏膜损伤的药物组合来解决上述问题。
发明内容
本发明要解决的技术问题是克服以上技术问题,提供一种治疗阿司匹林诱导胃黏膜损伤的药物组合,具有增加抗氧化因子SOD和降低脂质过氧化物MDA的作用。
为解决上述技术问题,本发明提供的技术方案为:一种治疗阿司匹林诱导胃黏膜损伤的药物组合,包括以下药物成分:茶多酚、枸杞多糖和生理盐水。
作为改进,包括以下重量配比的药物成分:茶多酚0.56~0.7份,枸杞多糖2.1~2.625份,生理盐水100份。
作为改进,该药物组合制作过程中在常温下遮光处理。
Nrf2-ARE信号通路作为内源性抗氧化应答机制信号通路之一,在氧化应激中占有重要的地位,Nrf2主要受Keap1(Kelch-1ike ECH-associatedprotein l)调节,通常情况下Nrf2以抑制状态被Keap1耦联;但在氧化应激条件下,被磷酸化的Nrf2与Keap1解耦联后进入胞核内与抗氧化反应元件(ARE)结合,使ARE调控的超氧化物歧化酶(SOD)、HO-1等抗氧化酶的基因表达增强,超氧化物歧化酶(SOD)处于氧化应激防御系统的第一位置,能够通过还原反应清除超氧阴离子自由基,将其转化成过氧化氢,从而阻断了自由基的连锁反应,保护细胞免受超氧阴离子自由基的损伤,是机体中一类重要的抗氧化酶,包括铜锌超氧化物歧化酶(SOD1)、锰超氧化物歧化酶(SOD2)和铁超氧化物歧化酶(SOD3)。
茶多酚(TP)是茶叶中一种主要活性物质,是天然的抗氧化剂,具有清除自由基,抗癌、抗辐射损伤等作用,研究表明,茶多酚中含量最高的表没食子儿茶素没食子酸酯(EGCG)可通过抑制NF-κB的活性调低了TNF-αmRNA的产生和翻译,从而抑制炎症反应,并强有力的抑制IL-lβ信号转导途径;
枸杞多糖(LBP)为枸杞果实中提取的水溶性多糖,是枸杞的主要生物活性物质,具有抗氧化、抗肿瘤、降血糖和血脂、免疫调节和神经保护等生物功效,枸杞多糖的抗氧化机制,主要涉及清除自由基、增强抗氧化酶的活性、减轻氧化应激损伤等方式。
动物实验显示,枸杞多糖能显著提高大鼠血清性激素水平和SOD活性,降低MDA水平,减轻活性氧自由基对粘膜上皮细胞的损伤。
采用以上配方后,本发明具有如下优点:本发明中当多酚和多糖进行物理混合时,体系主要以氢键、疏水相互作用、离子作用等非共价相互作用为驱动力,诱导两者形成可逆或不可逆多酚-多糖复合物,其中多糖包埋多酚是通过两步实现:首先多糖表面的羟基与水形成刚性结构,多糖内部形成疏水空腔或间隙;接着疏水相互作用力驱使低溶解性的多酚进入空腔或间隙,疏水相互作用被认为是多酚-多糖结合的主要驱动力,氢键能够增强其结合效果,通过多糖包埋的方法可以提高多酚的水溶性和稳定性,进而提高多酚的生物利用率;
茶多酚和枸杞多糖均具有较强的活性氧自由基清除作用,并且茶多酚还具有抗炎作用,在胃黏膜损伤修复方面发挥重要作用,通过茶多酚联合枸杞多糖在提高茶多酚生物活性的基础上,同时发挥二者对胃黏膜损伤的协同保护作用。
上述概述仅仅是为了说明书的目的,并不意图以任何方式进行限制。除上述描述的示意性的方面、实施方式和特征之外,通过参考附图和以下的详细描述,本发明进一步的方面、实施方式和特征将会是容易明白的。
附图说明
图1是本发明实验中各组小鼠体重变化曲线图。
图2是本发明实验中正常组HE染色观察小鼠胃粘膜组织放大图。
图3是本发明实验中胃粘膜损伤模型组HE染色观察小鼠胃粘膜组织放大图。
图4是本发明实验中LBP组HE染色观察小鼠胃粘膜组织放大图。
图5是本发明实验中TP组HE染色观察小鼠胃粘膜组织放大图。
图6是本发明实验中TP+LBP联合组HE染色观察小鼠胃粘膜组织放大图。
图7是本发明实验中免疫组织化学法(IHC)检测胃黏膜组织中抗氧化因子SOD1的表达(200×)。
图8是本发明实验中免疫组织化学法(IHC)检测胃黏膜组织中炎症信号通路因子NF-κB的表达(200×)。
为了更清楚地说明本申请实施例或现有技术中的技术方案,下面将对实施例或有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本申请的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
具体实施方式
在下文中,仅简单地描述了某些示例性实施例。正如本领域技术人员可认识到的那样,在不脱离本发明的精神或范围的情况下,可通过各种不同方式修改所描述的实施例。因此,附图和描述被认为本质上是示例性的而非限制性的。
下面结合附图对本发明的实施例进行详细说明。
结合附图1,一种治疗阿司匹林诱导胃黏膜损伤的药物组合,包括以下药物成分:茶多酚、枸杞多糖和生理盐水,其中重量配比如下:茶多酚0.56~0.7份,枸杞多糖2.1~2.625份,生理盐水100份,该药物组合制作过程中在常温下遮光处理。
实验验证
实验动物:6~8周龄,雄性SPF级昆明小鼠,28~35g,动物饲养及实验过程中保持室内恒温22~25℃,供给充足的食物和水分,定时更换垫料,为了不干扰动物昼夜生物节律,保证实验动物处于明、暗周期各12h;
实验分组及实验处理:
6~8周龄(28~35g)、雄性、SPF清洁级昆明小鼠40只,将小鼠随机分为5组,即正常组、胃黏膜损伤模型组(模型组)、茶多酚治疗组(TP组)、枸杞多糖治疗组(LBP组)、茶多酚联合枸杞多糖治疗组(联合治疗组),每组8只小鼠,实验分为两阶段进行:第一阶段为建模阶段,为期6天,第二阶段为治疗阶段,为期6天;
第一阶段:正常组小鼠灌胃0.9%的生理盐水0.1ml;模型组、LBP组、TP组、联合组小鼠均以200mg/kg体重的剂量将阿司匹林药物溶于0.1ml生理盐水并进行灌胃,一天一次,连续灌胃6天;
第二阶段:正常组和模型组小鼠灌胃0.9%生理盐水0.1ml;LBP组小鼠按75mg/kg体重灌胃溶于0.1ml生理盐水的枸杞多糖;TP组小鼠按20mg/kg体重灌胃溶于0.1ml生理盐水的茶多酚;联合组小鼠按TP 20mg/kg体重和LBP 75mg/kg体重溶于0.1ml生理盐水给小鼠灌胃,一天两次,共6天;
结果分析
1、小鼠体重变化曲线
从建立损伤模型前称量并记录小鼠初始体重,之后每天的同一时间称量小鼠体重,结束实验前称量并记录最终体重,利用小鼠整个实验期间的体重变化绘制体重变化曲线,由各组小鼠体重变化曲线可知每组小鼠体重总体均呈上升趋势;阿司匹林建模期间(第1-6天),各组小鼠的体重增长速率均缓慢,给药后(第7-12天),联合组小鼠体重增长速率相比于模型组、TP组和LBP组小鼠显著上升,详情见附图1;
2、Guth评分标准计算溃疡指数
利用Guth评分标准计算胃粘膜损伤指数并累计计分得到溃疡指数,正常组小鼠胃黏膜无溃疡发生,模型组溃疡指数为9.67±1.366,与模型组小鼠相比,LBP组、TP组和联合用药组小鼠胃黏膜溃疡指数均具有显著性(P<0.05);且联合用药组小鼠与LBP组、TB组小鼠相比,溃疡指数降低更显著(P<0.05),详情见下表:
注:n=8,与模型组相比,*表示显著(P<0.05);与联合组相比,#表示显著(P<0.05)
3、各组溃疡抑制率对比
溃疡抑制率=(模型对照组溃疡指数-给药组溃疡指数)/模型对照组溃疡指数×100%
与正常组小鼠相比,模型组小鼠的胃溃疡面明显,LBP组、TP组、联合组小鼠的溃疡抑制率分别为25.86%、29.31%、72.41%,联合组胃溃疡的抑制率比LBP组、TB组小鼠的溃疡抑制率有明显的提高,实验结果表明,TP联合LBP治疗阿司匹林诱导的胃黏膜损伤在降低胃黏膜溃疡率方面呈现了一定的协同效应;
4、组织病理切片观察
在HE染色镜下观察可见正常对照组小鼠胃黏膜组织切片黏膜无损伤、结构完整,腺体排列紧密整齐,未见黏膜出血及水肿;阿司匹林模型组小鼠胃黏膜组织切片黏膜结构紊乱,上皮细胞脱落,部分区域上皮层缺失,黏膜下血管内有明显的扩张充血并伴不同程度的弥漫性出血、水肿及大量炎性细胞浸润;TP组和LBP组小鼠胃黏膜组织切片可见胃黏膜损伤有一定程度的减轻,上皮细胞脱落减少,黏膜下出血减轻,少量炎性细胞浸润;联合用药组小鼠胃黏膜组织切片胃黏膜上皮细胞完整,腺体结构较整齐,黏膜水肿轻微,未见出血及炎性细胞浸润;实验结果表明,TP联合LBP治疗阿司匹林诱导的胃黏膜损伤在修复损伤和降低炎症反应方面呈现了一定的协同效应,详情见图2~图6;
5、小鼠血清和组织匀浆中T-SOD活性及MDA含量
各组小鼠血清中T-SOD活性和MDA含量比较,与正常组小鼠血清相比,阿司匹林模型组小鼠血清中T-SOD活性升高且具有显著性(P<0.05),MDA含量显著增高(P<0.05);与模型组小鼠血清相比,TP组和LBP组小鼠血清中T-SOD活性均升高但不具有显著性(P>0.05),MDA含量均显著降低(P<0.05);与枸杞多糖和茶多酚组小鼠血清相比,联合组小鼠血清中T-SOD活性显著升高(P<0.05),MDA含量均显著降低(P<0.05),详情见下表:
注:n=8,与正常组相比,%表示显著(P<0.05);与模型组相比,*表示显著(P<0.05);与联合组相比,#表示显著(P<0.05)
各组小鼠胃黏膜组织匀浆中T-SOD活性和MDA含量比较,与正常组小鼠胃黏膜组织匀浆相比,阿司匹林模型组小鼠胃黏膜组织匀浆中T-SOD活性升高且具有显著性(P<0.05),MDA含量显著增高(P<0.05);与模型组小鼠胃黏膜组织匀浆相比,TP组和LBP组小鼠胃黏膜组织匀浆中T-SOD活性均显著升高(P<0.05),MDA含量均显著降低(P<0.05);与TP组和LBP组小鼠胃黏膜组织匀浆相比,联合组小鼠胃黏膜组织匀浆中T-SOD活性显著升高(P<0.05),MDA含量均显著降低(P<0.05);实验结果表明,TP联合LBP治疗阿司匹林诱导的胃黏膜损伤在抗氧化方面呈现了一定的协同效应,详情见下表:
注:n=8,与正常组相比,%表示显著(P<0.05);与模型组相比,*表示显著(P<0.05);与联合组相比,#表示显著(P<0.05);
6、IHC实验
检测SOD1结果显示,阿司匹林诱导小鼠胃黏膜损伤后,胃黏膜组织中抗氧化的SOD1表达水平明显降低,经过单独的TP或LBP治疗后,胃黏膜组织中抗氧化因子SOD1表达水平均上调,而TP联合LBP治疗则更显著提高了胃黏膜组织中SOD1的表达水平,实验结果表明,TP联合LBP治疗阿司匹林诱导的胃黏膜损伤在抗氧化方面呈现了一定的协同效应,详情见图7;
检测NF-κB结果显示,阿司匹林诱导小鼠胃黏膜损伤后,胃黏膜组织中炎症反应信号通路关键因子NF-κB的表达水平明显提高,单独TP治疗显著下调了胃粘膜组织中NF-κB的表达,单独LBP治疗后则未表现出对NF-κB表达的调节作用,而TP联合LBP治疗进一步降低了胃黏膜组织中NF-κB的表达水平,该结果表明,TP联合LBP治疗在抑制阿司匹林诱导胃黏膜损伤的炎症反应方面,表现出了一定的协同效应,详请见图8。
本发明就枸杞多糖联合茶多酚对阿司匹林诱导胃黏膜损伤的治疗作用进行了一系列动物实验,综合上述实验结果表明,茶多酚联合枸杞多糖用药对阿司匹林诱导损伤的胃黏膜具有协同保护作用,本发明通过记录小鼠体重变化、对损伤胃粘膜进行Guth评分并计算溃疡抑制率、对胃黏膜组织进行组织病理切片观察、对胃黏膜组织通过IHC检测SOD1和NF-κB、利用羟胺法和TBA法测量小鼠血清和组织匀浆中总超氧化物歧化酶(T-SOD)的活性值以及MDA的含量水平,以达到说明联合使用茶多酚和枸杞多糖对阿司匹林诱导的胃黏膜损伤的机体具有增加抗氧化因子SOD和降低脂质过氧化物MDA的作用,从而确定枸杞多糖和茶多酚在联合用药时可以对阿司匹林诱导的胃黏膜损伤起到协同保护作用。
以上对本发明及其实施方式进行了描述,这种描述没有限制性,附图中所示的也只是本发明的实施方式之一,实际的实施例并不局限于此。总而言之,如果本领域的普通技术人员受其启示,在不脱离本发明创造宗旨的情况下,不经创造性的设计出与该技术方案相似的结构方式及实施例,均应属于本发明的保护范围。
Claims (2)
1.一种药物组合物在制备治疗阿司匹林诱导胃黏膜损伤的药物中的用途,其特征在于:所述药物组合物由以下药物成分组成:茶多酚0.56~0.7份,枸杞多糖2.1~2.625份,生理盐水100份。
2.根据权利要求1所述的一种药物组合物在制备治疗阿司匹林诱导胃黏膜损伤的药物中的用途,其特征在于:该药物组合制作过程中在常温下遮光处理。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211476101.7A CN115737727B (zh) | 2022-11-23 | 2022-11-23 | 一种治疗阿司匹林诱导胃黏膜损伤的药物组合 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211476101.7A CN115737727B (zh) | 2022-11-23 | 2022-11-23 | 一种治疗阿司匹林诱导胃黏膜损伤的药物组合 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115737727A CN115737727A (zh) | 2023-03-07 |
CN115737727B true CN115737727B (zh) | 2024-03-01 |
Family
ID=85336250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211476101.7A Active CN115737727B (zh) | 2022-11-23 | 2022-11-23 | 一种治疗阿司匹林诱导胃黏膜损伤的药物组合 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115737727B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030025538A (ko) * | 2001-09-21 | 2003-03-29 | 주식회사 겟웰바이오 | 데커시놀을 포함하는 살리실산염 유도체-유발성 위점막손상의 예방 및 치료용 조성물 |
CN101926818A (zh) * | 2008-12-25 | 2010-12-29 | 天津康鸿医药科技发展有限公司 | 一种含有茶多酚和海藻酸的药物组合及其用途 |
CN101933894A (zh) * | 2009-07-03 | 2011-01-05 | 张清 | 胃肠粘膜保护胶 |
CN103110684A (zh) * | 2012-02-14 | 2013-05-22 | 甘肃创兴生物工程有限责任公司 | 对胃黏膜有辅助保护作用软胶囊及其制备方法 |
CN105166862A (zh) * | 2015-08-12 | 2015-12-23 | 天津科技大学 | 高稳定性纤维素基天然食用花青素色素复合物的制备方法 |
CN105495620A (zh) * | 2016-01-08 | 2016-04-20 | 贵州赤水国礼金钗石斛发展有限公司 | 一种同时具有免疫增强及降血脂功能的植物提取物组合物 |
CN107080251A (zh) * | 2017-04-10 | 2017-08-22 | 新乡医学院 | 一种具有减肥功能的绿茶多酚组合物及其制备方法 |
-
2022
- 2022-11-23 CN CN202211476101.7A patent/CN115737727B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030025538A (ko) * | 2001-09-21 | 2003-03-29 | 주식회사 겟웰바이오 | 데커시놀을 포함하는 살리실산염 유도체-유발성 위점막손상의 예방 및 치료용 조성물 |
CN101926818A (zh) * | 2008-12-25 | 2010-12-29 | 天津康鸿医药科技发展有限公司 | 一种含有茶多酚和海藻酸的药物组合及其用途 |
CN101933894A (zh) * | 2009-07-03 | 2011-01-05 | 张清 | 胃肠粘膜保护胶 |
CN103110684A (zh) * | 2012-02-14 | 2013-05-22 | 甘肃创兴生物工程有限责任公司 | 对胃黏膜有辅助保护作用软胶囊及其制备方法 |
CN105166862A (zh) * | 2015-08-12 | 2015-12-23 | 天津科技大学 | 高稳定性纤维素基天然食用花青素色素复合物的制备方法 |
CN105495620A (zh) * | 2016-01-08 | 2016-04-20 | 贵州赤水国礼金钗石斛发展有限公司 | 一种同时具有免疫增强及降血脂功能的植物提取物组合物 |
CN107080251A (zh) * | 2017-04-10 | 2017-08-22 | 新乡医学院 | 一种具有减肥功能的绿茶多酚组合物及其制备方法 |
Non-Patent Citations (6)
Title |
---|
余婷.关于太和堂镇农村居民感染泌尿系统疾患的调查报告.《中国校外教育》.2013,(第21期),第33、61页. * |
张一芳,等.枸杞多糖对大鼠实验性胃溃疡的作用研究.《中国药业》.2011,第20卷(第01期),第14-15页. * |
张雅莉,等.枸杞多糖及其配伍茶多酚缓解小鼠体力疲劳作用的研究.《上海交通大学学报(医学版)》.2016,第36卷(第05期),第662页右栏"分组及剂量设置"项下. * |
汪玉兰,等.茶多酚对雷公藤甲素致小鼠胃粘膜损伤的保护作用.《皖南医学院学报》.2006,第25卷(第03期),第174-176页. * |
胡任重,等.枸杞多糖对应激性溃疡大鼠胃组织TNF-α和CGRP表达的影响.《中国现代医生》.2012,第50卷(第13期),第6页左栏第1段,第7页右栏第2段. * |
陈寿宏编著.《中华食材 下》.合肥工业大学出版社,2016,第1247页倒数第2段. * |
Also Published As
Publication number | Publication date |
---|---|
CN115737727A (zh) | 2023-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nabavizadeh et al. | Gastroprotective effects of Stachys Lavandulifolia extract on experimental gastric ulcer | |
Uduak et al. | Ulceroprotective effect of methanol extract of Psidium guajava leaves on ethanol induced gastric ulcer in adult wistar rats | |
Cyriac et al. | Anti-hyperglycemic effect of aqueous extract of Kappaphycus alvarezii (Doty) Doty ex. P. Silva in alloxan-induced diabetic rats | |
Caban et al. | Polyphenols and the potential mechanisms of their therapeutic benefits against inflammatory bowel diseases | |
KR102156731B1 (ko) | 염증후 색소과다침착의 치료를 위한 바쿠치올 조성물 | |
KR101880954B1 (ko) | 셀레늄화 변형된 유근피 유래의 다당류 및 이를 포함하는 항산화용 조성물 | |
CN115737727B (zh) | 一种治疗阿司匹林诱导胃黏膜损伤的药物组合 | |
KR20090091547A (ko) | 항염 및 피부자극완화용 화장료 조성물 | |
CN102772471B (zh) | 一种蓝莓果皮提取物及其在制备抗肝损伤药物中的应用 | |
Rethinam et al. | Health benefits of coconut water | |
KR101009904B1 (ko) | 천연 식물 추출물을 포함하는 항염 조성물 | |
KR101958969B1 (ko) | 해조류 복합추출물 및 식물 복합추출물을 유효성분으로 함유하는 알코올성 위장질환의 개선, 예방 또는 치료용 조성물 | |
US20220401379A1 (en) | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation | |
CN112870331B (zh) | 一种防治酒精性肝损伤的组合物及其制备方法与应用 | |
Mascolo et al. | Healing powers of aloes | |
Kheirandish et al. | Protective effect of trigonella foenum graecum (fenugreek) seed extract on experimental intestinal ischemia/reperfusion injury in rats | |
US11484562B2 (en) | Composition for preventing or treating obesity comprising natural mixture extracts | |
KR20080101848A (ko) | 숙취예방 및 해소를 위한 생약 추출물 및 이를 이용한 기능성 식품 | |
Ekpenyong et al. | Cocos Nucifera Water: Therapeutic Benefits and Sickle Cell Anaemiaa Review | |
KR100778942B1 (ko) | 항염증 효과를 나타내는 소나무잔나비버섯 추출물 및 그용도 | |
Ahajumobi et al. | Afro Medicinal Plants a Promising Remedy for Sickle Cell Anemia | |
Liu et al. | Protective effect of propolis ethanol extract on ethanol-induced renal toxicity: an in vivo study | |
KR102627108B1 (ko) | 벌나무 추출물 및 버섯 추출물의 혼합물을 유효성분으로 포함하는 비알코올성 지방간의 예방, 개선 또는 치료용 약학적 조성물 및 이의 제조방법 | |
KR20120113186A (ko) | 생약재 혼합 추출물을 포함하는 위장질환의 예방 또는 치료용 조성물 | |
Nur et al. | Gastroprotective Activity of Nutmeg Flesh Extract (Myristica Fragrans Houtt.) on Acetosal-Induced White Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |